Author

Joan Ronan

Institution: Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Observed institutions: Harvard University, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

OpenAlex ID: A5076716280

Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)

2024 · Theodore W. Laetsch, Stephan Voss, et al. · Journal of Clinical Oncology · 20

Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.

2023 · Theodore Willis Laetsch, Kathleen Ludwig, et al. · Journal of Clinical Oncology · 5

A phase II study of larotrectinib for children with newly diagnosed solid tumors and relapsed acute leukemias harboring TRK fusions: Children’s Oncology Group study ADVL1823.

2020 · Theodore Willis Laetsch, Kathleen Ludwig, et al. · Journal of Clinical Oncology · 2

Works count: 3

Citation count: 27

H-index: 2

I10-index: 1